Literature DB >> 8825459

Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site.

F S Jensen1, L R Nielsen, M Schwartz.   

Abstract

Ten individuals registered at the Danish Cholinesterase Research Unit were examined at the DNA level for the presence of the K allele of plasma cholinesterase, using amplification-created restriction sites (ACRSs). A further nine members of a family registered at the unit were tested for mutations of the K and atypical variants. The frequency of the K allele was calculated from examination of normal material from 25 individuals, representing 50 random alleles. The results show that the ACRS method successfully demonstrates the presence of the K variant, whose frequency in the Danish population was found to be 0.18. We conclude that this technique is a reliable and rapid non-radioactive diagnostic assay for detecting the plasma cholinesterase K variant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825459     DOI: 10.1159/000154321

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  9 in total

1.  The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

Authors:  P G Kehoe; H Williams; P Holmans; G Wilcock; N J Cairns; J Neal; M J Owen
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

2.  Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

Authors:  C Holmes; C Ballard; D Lehmann; A David Smith; H Beaumont; I N Day; M Nadeem Khan; S Lovestone; M McCulley; C M Morris; D G Munoz; K O'Brien; C Russ; T Del Ser; D Warden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

3.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

4.  Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.

Authors:  S P McIlroy; V L Crawford; K B Dynan; B M McGleenon; M D Vahidassr; J T Lawson; A P Passmore
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

5.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

6.  Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population.

Authors:  Melih O Babaoglu; Turgay Ocal; Banu Bayar; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-01-21       Impact factor: 2.953

7.  Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2009-08-15       Impact factor: 2.316

8.  Butyrylcholinesterase genotype and enzyme activity in relation to Gulf War illness: preliminary evidence of gene-exposure interaction from a case-control study of 1991 Gulf War veterans.

Authors:  Lea Steele; Oksana Lockridge; Mary M Gerkovich; Mary R Cook; Antonio Sastre
Journal:  Environ Health       Date:  2015-01-09       Impact factor: 5.984

9.  Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.

Authors:  Natsalil Pongthanaracht; Somchai Yanarojana; Darawan Pinthong; Supeenun Unchern; Amnuay Thithapandha; Prasert Assantachai; Porntip Supavilai
Journal:  Clin Interv Aging       Date:  2017-05-26       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.